ConexiantGLP-1 Drugs Examined in Psychiatric Outcomes

A Swedish national cohort of 95,490 patients with depression or anxiety finds semaglutide associated with a 42% lower risk of worsening mental illness compared to periods of nonuse. The within-patient design reduces confounding, making this among the strongest real-world psychiatric data yet on GLP-1 receptor agonists.

Clinical Considerations

• Semaglutide reduced a composite of psychiatric hospitalization, self-harm, suicide, and extended sick leave, not just symptom scores
• Benefits were molecule-specific: liraglutide showed modest effects on depression only; exenatide and dulaglutide showed no psychiatric benefit
• Semaglutide was also associated with lower risk of worsening substance use disorder, extending implications beyond mood disorders
• GLP-1 receptor agonists as a class were associated with reduced self-harm risk, regardless of specific agent

Practice Applications

• Flag psychiatric patients already prescribed semaglutide for diabetes as potentially deriving mental health benefit worth monitoring
• Discuss GLP-1 options with prescribing physicians when patients with comorbid depression or anxiety require antidiabetic therapy
• Track psychiatric outcomes — hospitalization, self-harm episodes, sick leave — in patients initiating or discontinuing semaglutide
• Avoid assuming class-level equivalence; document which GLP-1 agent patients receive, as psychiatric effects differ significantly by molecule

More in GLP-1s